A Phase III Randomized Open-label Multi-center Study of Ruxolitinib Versus Best Available Therapy in Patients With Corticosteroid-refractory Acute Graft vs. Host Disease After Allogeneic Stem Cell Transplantation
Phase of Trial: Phase III
Latest Information Update: 19 Apr 2018
At a glance
- Drugs Ruxolitinib (Primary)
- Indications Graft-versus-host disease
- Focus Registrational; Therapeutic Use
- Acronyms REACH2
- Sponsors Novartis
- 19 Feb 2018 Planned primary completion date changed from 30 Nov 2018 to 14 Jun 2019.
- 13 Oct 2017 Planned End Date changed from 24 Apr 2019 to 9 Apr 2021.
- 06 Sep 2017 Planned End Date changed from 30 Sep 2020 to 24 Apr 2019.